NOVARTIS Stock London S.E.
Stocks
0HKE
CH0012005267
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - GBX | - |
|
| Market Cap | 298B 259B 241B 222B 419B 28,478B 425B 2,845B 1,117B 14,178B 1,120B 1,096B 47,540B | P/E 2026 * |
22.3x | P/E 2027 * | 19x |
|---|---|---|---|---|---|
| Enterprise Value | 331B 288B 268B 246B 465B 31,640B 472B 3,161B 1,241B 15,752B 1,245B 1,217B 52,817B | EV / Sales 2026 * |
5.76x | EV / Sales 2027 * | 5.34x |
| Free-Float |
91.66% | Yield 2026 * |
2.78% | Yield 2027 * | 2.9% |
Last Transcript: NOVARTIS
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 2018-01-31 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 2026-03-15 |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 64 | 2022-05-15 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 2014-12-31 |
| Director/Board Member | 69 | 2015-12-31 | |
Ton Büchner
BRD | Director/Board Member | 61 | 2015-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.53% | -3.95% | +55.23% | +152.74% | 1,030B | |
| +0.21% | -2.68% | +55.61% | +53.02% | 617B | |
| -2.51% | -3.25% | +32.76% | +67.76% | 455B | |
| +0.06% | +1.17% | +36.21% | +31.25% | 350B | |
| -0.69% | -0.44% | +9.86% | +14.23% | 265B | |
| -7.37% | -4.31% | -5.69% | -41.99% | 225B | |
| -0.64% | +2.43% | +30.52% | +64.49% | 209B | |
| -0.82% | +0.70% | +15.96% | +71.01% | 163B | |
| +0.40% | +1.92% | +7.39% | -30.64% | 142B | |
| Average | -1.12% | +4.58% | +26.43% | +42.43% | 383.99B | |
| Weighted average by Cap. | -0.83% | +4.84% | +37.65% | +71.41% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 57.58B 50.06B 46.59B 42.78B 80.78B 5,497B 82.03B 549B 216B 2,737B 216B 212B 9,176B | 61.12B 53.13B 49.46B 45.41B 85.75B 5,835B 87.08B 583B 229B 2,905B 230B 225B 9,740B |
| Net income | 13.78B 11.98B 11.15B 10.24B 19.33B 1,315B 19.63B 131B 51.58B 655B 51.75B 50.62B 2,196B | 15.36B 13.35B 12.43B 11.41B 21.54B 1,466B 21.88B 146B 57.49B 730B 57.68B 56.41B 2,447B |
| Net Debt | 33.11B 28.79B 26.79B 24.6B 46.45B 3,161B 47.17B 316B 124B 1,574B 124B 122B 5,277B | 27.82B 24.18B 22.51B 20.66B 39.02B 2,655B 39.63B 265B 104B 1,322B 104B 102B 4,433B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- NOVN Stock
- 0HKE Stock
Select your edition
All financial news and data tailored to specific country editions
